SAADA-BOUZID , E.

Last name: SAADA-BOUZID

First name: E.

August 2021 (v1)

Journal article

Metadata-only

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

Pautier, P. Floquet, A. Chevreau, C.

Background: Uterine leiomyosarcomas (U-LMSs) and soft tissue leiomyosarcomas (ST-LMSs) are rare tumours with poor prognosis when locally advanced or metastatic, and with moderate chemosensitivity. In 2015 we reported very encouraging results of the LMS-02 study (NCT02131480) with manageable toxicity. Herein, we report the updated and long-term...

Uploaded on: December 3, 2022
April 2022 (v1)

Journal article

Metadata-only

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)

Moreau-Bachelard, C. Campion, L. Toulmonde, M.

Background: Synovial sarcoma (SS) occurs in both adult and pediatric patients. The primary aim of this study is to describe the outcomes, prognostic factors, and treatment of patients with metastatic SS within a nationwide cohort.Patients and methods: All pediatric and adult patients with metastatic SS are registered in the French Sarcoma Group...

Uploaded on: December 3, 2022
2024 (v1)

Journal article

Metadata-only

Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial

Guigay, J. Ortholan, C. Vansteene, D.

BACKGROUND: At present, there is no established standard treatment for frail older patients with recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the efficacy and safety of cetuximab to those of methotrexate (the reference regimen) in this population. METHODS: This randomised, open-label, phase 3 trial was done...

Uploaded on: July 27, 2024

SAADA-BOUZID , E.

Recent uploads